In the third quarter, Commerzbank Aktiengesellschaft FI trimmed its position in AbbVie by 30.5%, selling 39,586 shares and reducing its holding to 90,102 shares. At the end of the period, the remaining stake was valued at approximately $20.86 million, reflecting the bank’s decision to reallocate capital. This divestiture follows a broader trend among institutional investors: Norges Bank initiated a new position in Q2 valued at $4.29 billion, while Vanguard Group increased its stake by 1.9% to 177.3 million shares, and DZ BANK more than doubled its holdings to 4.72 million shares. Overall, institutional ownership stands at 70.23%, underscoring AbbVie’s continued appeal among large asset managers even as some funds adjust their exposure.

AbbVie reported Q3 revenue of $15.78 billion, a 9.1% year-over-year increase, surpassing analysts’ consensus by $200 million. Earnings per share came in at $1.86, $0.09 above forecasts, driven by robust performance in immunology and oncology portfolios. Net margin held at 4.0%, while return on equity reached an exceptional 3,216.5%, boosted by share repurchases and disciplined cost management. Management reiterated full-year guidance of $3.32 to $3.36 EPS for Q4, setting the company on pace to deliver annual earnings of approximately $12.31 per share, supported by strong cash generation and ongoing pipeline milestones in neuroscience and women’s health.

AbbVie declared a quarterly dividend of $1.73 per share, payable February 17 to holders of record on January 16, marking a 5.5% increase from the prior payout. This raises the annualized dividend to $6.92, representing a yield of 3.2% and a payout ratio of 524%. On the research front, two analysts maintain a Strong Buy rating, thirteen issue Buy recommendations and eight recommend Hold, resulting in a consensus Moderate Buy stance. Price targets range from $235 to $275, with a mean objective of $248.11, reflecting expectations that AbbVie’s diversified therapeutics pipeline and capital return strategy will sustain shareholder value in 2026.